2025
Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia – Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis
Zeidan A, Yu R, Wang Y, Lan Z, Grinblatt D, Elsouda D, Spalding J, Block A, Touya M, Walker M, Pandya B. Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia – Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis. Acta Haematologica 2025, 1-12. PMID: 40228486, PMCID: PMC12112888, DOI: 10.1159/000545384.Peer-Reviewed Original ResearchAcute myeloid leukemiaReal-world overall survivalAcute myeloid leukemia diagnosisReal-world time to next treatmentTreatment patternsFLT3-TKIMyeloid leukemiaClinical outcomesMedian real-world overall survivalTime to next treatmentClinical outcomes of patientsFLT3 tyrosine kinase inhibitorsReal-world treatment patternsAcute myeloid leukemia patientsFMS-like tyrosine kinase 3R/R AML patientsHigh-intensity chemotherapyOutcomes of patientsRetrospective cohort studyTyrosine kinase 3Retrospective longitudinal studyFirst relapseOverall survivalAML patientsFLT3 mutations
2020
Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes
Zeidan A, Gilligan A, Gautam S, Grinblatt D, Elsouda D, Sullivan L, Pandya B. Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes. Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-136366.Peer-Reviewed Original ResearchFLT3 tyrosine kinase inhibitorsAcute myeloid leukemiaTyrosine kinase inhibitorsMedian overall survivalOverall survivalFLT3 mutation statusTreatment patternsR settingTKI useAML patientsFMS-like tyrosine kinase 3 (FLT3) mutationsMutation statusDiagnosis of AMLTyrosine kinase 3 mutationsElectronic medical record dataEligible adult patientsHigh-intensity chemotherapyOngoing retrospective studyPost-treated patientsAstellas PharmaRetrospective cohort studySystemic anticancer therapyKaplan-Meier analysisReal-world treatmentTesting trends
2019
Streamline - Study of Relapse or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study
Zeidan A, Gilligan A, Gautam S, Hu N, Grinblatt D, Pandya B. Streamline - Study of Relapse or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study. Blood 2019, 134: 5082. DOI: 10.1182/blood-2019-123535.Peer-Reviewed Original ResearchR AMLHigh-intensity chemotherapyLow-intensity chemotherapyBest supportive careAcute myeloid leukemiaFLT3 mutational statusMajority of ptsElectronic medical recordsFLT3 inhibitorsDifferent anticancer therapiesMutational statusCohort studyInitial diagnosisEMR databaseFMS-like tyrosine kinase 3 (FLT3) mutationsTyrosine kinase 3 mutationsStudy periodSubset of ptsObservational cohort studyRetrospective cohort studyClinical research nursesAnticancer therapyConfirmation of diagnosisImportant therapeutic innovationsInitial AML diagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply